We collected 75 primary @entity2 with @entity1358 , or sarcomatous elements to better define their clinical, histologic, and immunohistochemical profile. The @entity1 's age ranged from 42 to 81 years (mean 65 years), and the male-to-female ratio was 9.7:1. Sixty-nine @entity1 (92%) were smokers. Cough and hemoptysis were the most frequent presenting symptoms. Fifty-nine @entity1 (65%) died of disease: only stage significantly predicts overall survival (p = 0.0273). Microscopically, based on the WHO criteria, 58 cases were classified as @entity189 (51 with an epithelial component, 7 composed exclusively of spindle and giant cells), 10 as @entity189 , 3 as @entity7468 , 3 as @entity6962 , and 1 as @entity8523 . Immunohistochemically, in the @entity5 composed exclusively of spindle and/or giant cells, @entity7457 ( @entity7457 ) and @entity5822 were positive in 55% and 70% of the cases, respectively, whereas @entity3231 was always negative. In @entity189 with an epithelial component, @entity5822 , @entity7457 , and @entity3231 were positive in the sarcomatoid component in 62.7%, 43.1%, and 5.9% of the cases, respectively, whereas they were always negative in the sarcomatous part of @entity6962 and @entity8523 . In the epithelial component of @entity189 , @entity5822 , @entity7457 , and @entity3231 were positive in 76.4%, 58.8%, and 39.2% of the cases, respectively, whereas the same antibodies did not react with the epithelial component of @entity6962 ; in the case of @entity8523 , the epithelial part of the @entity5 was positive for @entity5822 and @entity7457 , whereas it was negative for @entity3231 . @entity2225 was always negative. In our opinion, this study: 1) supports the metaplastic histogenetic theory for this group of @entity5 ; 2) shows that @entity5822 and @entity7457 , but not @entity3231 , are useful immunohistochemical markers in this setting; 3) confirms that stage is at the moment the only significant prognostic parameter, as in conventional @entity1149 ; and 4) shows that this group of @entity5 has a worse prognosis than @entity1149 at surgically curable stages I, justifying their segregation as an independent histologic type in the WHO classification.

@entity2 with XXXX , or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity3231 :: ('653509', 'Gene') :: ['surfactant protein-A'] @entity7468 :: ('MESH:D018286', 'Disease') :: ['giant cell carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['pulmonary carcinomas'] @entity2225 :: ('54474', 'Gene') :: ['Cytokeratin 20'] @entity189 :: ('MESH:D002277', 'Disease') :: ['spindle cell carcinoma', 'pleomorphic carcinoma', 'pleomorphic carcinomas'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung carcinomas', 'conventional non-small cell lung carcinoma'] @entity8523 :: ('MESH:D018202', 'Disease') :: ['blastoma', 'pulmonary blastoma'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['pleomorphic, sarcomatoid'] @entity5822 :: ('3855', 'Gene') :: ['cytokeratin 7'] @entity7457 :: ('7080', 'Gene') :: ['thyroid transcription factor-1', 'TTF-1'] @entity6962 :: ('MESH:D002296', 'Disease') :: ['carcinosarcoma', 'carcinosarcomas']
@entity1358 :: (MESH:D002292,Disease) :: ['pleomorphic, sarcomatoid']
